Ali Iftikhar, Ahmad Wiqar, Ullah Arslan Rahat, Khan Faheemullah, Ijaz Muhammad, Khan Sheraz, Khan Tahir Mehmood
Pharmacy Unit, Paraplegic Center, Hayatabad, Peshawar, Khyber Pakhtunkhwa, Pakistan.
Department of Medicine, Northwest General Hospital & Research Center, Peshawar, Pakistan.
Hosp Pharm. 2021 Aug;56(4):384-391. doi: 10.1177/0018578720910401. Epub 2020 Apr 21.
Underreporting of adverse drug reactions (ADRs) is considered a major determinant of poor ADR signal detection in Pakistan. Considering this, the study was proposed to evaluate healthcare professionals' (HCPs) knowledge attitude toward and the barriers that discourse ADRs reporting. A cross-sectional survey was distributed among HCPs in 3 major tertiary care facilities of Peshawar. A self-administered, 31 items questionnaire was circulated online to collect the required information. Relative index ranking was used to identify the top barriers to the ADR reporting process. HCPs (n = 322) were requested, and over one-third (n = 122) responded. Of the total, 97 (79.5%) were males, and by designation, 59(48.4%) were resident medical officers. About 45% of the HCPs did not identify the appropriate pharmacovigilance (PV) definition. More than half of the HCPs (52.2%) distinguished the appropriate PV purpose. Nearly 80% HCPs did not know the acceptable reporting time frame, while 22.1% HCPs knew that regulatory body for ADRs does not exist in Pakistan. The majority (95.08%) of the HCPs either strongly agreed or agreed that reporting an ADRs is a professional obligation and all the HCPs were of the opinion that PV should be taught in detail to HCPs. Exploring the barriers, it was identified that the key barriers to ADRs reporting were "unavailability of professional environment to discuss ADRs," Relative Importance Index (RII) = 0.813, "lack of incentives for reporting" (RII = 0.774), "lack of knowledge regarding reporting" (RII = 0.693), and "insufficient knowledge of pharmacotherapy in detecting ADRs" (RII = 0.662). In addition to these, "complicated reporting forms" (RII = 0.616), "lack of motivation for reporting ADRs" (RII = 0.610), and "absence of professional confidence" were seen as major hindrances in effective reporting of ADRs (RII = 0.598). Concerning PV and ADR reporting poor knowledge was noted. However, the majority of the HCPs showed an explicit attitude regarding ADRs reporting. The majority of the HCPs disclosed unavailability of professional environment to discuss about ADRs, lack of incentives, and how to report the main factors hindering the ADRs reporting. It is emphasized that health authorities carve out a niche for a well purposeful PV center and pledge educational activities and trainings for increasing understanding and approaches regarding reporting of ADR.
在巴基斯坦,药物不良反应(ADR)报告不足被认为是ADR信号检测不佳的主要决定因素。考虑到这一点,本研究旨在评估医疗保健专业人员(HCP)对ADR报告的知识、态度以及妨碍ADR报告的障碍。在白沙瓦的3家主要三级医疗设施中,对HCP进行了横断面调查。通过在线发放一份包含31个条目的自填式问卷来收集所需信息。使用相对指数排名来确定ADR报告过程中的主要障碍。共邀请了322名HCP,超过三分之一(122名)做出了回应。其中,97名(79.5%)为男性,按职称划分,59名(48.4%)为住院医师。约45%的HCP未正确识别适当的药物警戒(PV)定义。超过一半的HCP(52.2%)明确了适当的PV目的。近80%的HCP不知道可接受的报告时间框架,而22.1%的HCP知道巴基斯坦不存在ADR的监管机构。大多数(95.08%)HCP强烈同意或同意报告ADR是一项专业义务,并且所有HCP都认为应该向HCP详细讲授PV。在探究障碍时发现,ADR报告的主要障碍是“缺乏讨论ADR的专业环境”,相对重要性指数(RII)=0.813,“报告缺乏激励措施”(RII = 0.774),“缺乏报告知识”(RII = 0.693),以及“在检测ADR方面药物治疗知识不足”(RII = 0.662)。除此之外,“报告表格复杂”(RII = 0.616),“报告ADR缺乏动力”(RII = 0.610),以及“缺乏专业信心”被视为有效报告ADR的主要障碍(RII = 0.598)。关于PV和ADR报告,发现知识水平较差。然而,大多数HCP对ADR报告表现出明确的态度。大多数HCP表示缺乏讨论ADR的专业环境、缺乏激励措施以及如何报告是阻碍ADR报告的主要因素。强调卫生当局应为一个目标明确的PV中心开辟空间,并承诺开展教育活动和培训,以提高对ADR报告的理解和方法。